Haber Trilix Advisors’s Puma Biotechnology PBYI Stock Holding History

Haber Trilix Advisors’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q2	$97K	Buy	+2,190	New	+$77.2K	0.01%	183

Other funds holding PBYI

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BCPEM

Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Haber Trilix Advisors's PBYI Position: Q2 2013 in Review

Haber Trilix Advisors opened a new position in Puma Biotechnology (PBYI) in Q2 2013: 2,190 shares worth $97K. The stake represents 0.01% of the portfolio and ranks #183 among its holdings.

84 funds tracked by Wall St. Rank hold PBYI as of Q2 2013.

Haber Trilix Advisors held 2,190 shares of Puma Biotechnology worth $97K as of Q2 2013.
Puma Biotechnology was a new Haber Trilix Advisors position in Q2 2013.
Puma Biotechnology made up 0.01% of Haber Trilix Advisors's portfolio in Q2 2013, its #183 holding.
84 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2013.

Based on Haber Trilix Advisors's 13F filing for Q2 2013, filed 14 Aug 2013.